Skip to main content

NEURAL TRANSPLANTATION IN THE TREATMENT OF PATIENTS WITH PARKINSON’S DISEASE

Objective

There are currently no cures for Parkinson's disease (PD) but one of the most effective reparative therapies in patients to date has been with allotransplants of dopamine (DA) neuroblasts obtained from fetal ventral mesencephalic (VM) tissue. However, this cell transplantation approach has given inconsistent results, with some patients doing extremely well and coming off anti-PD medication for years, whilst others have shown no or only modest clinical improvements, and in some cases also developed severe, off-state graft-induced dyskinesias (GIDs). The reasons behind this heterogeneity of outcomes, and the emergence of GIDs in particular, need to be better understood, not least in the perspective of the rapid advances that are now being made in the development of stem-cell based therapies. There is therefore an urgent need to revisit the trials that have already been done with fetal VM tissue in PD patients, with the expectation that a critical reassessment can form the basis for an optimised and more standardised procedure that will translate into more consistently efficacious transplants with minimal side-effects. Over the last two years a group of international experts, including the key investigators of the previous European and North American trials, has been re-examining the outcome of these trials as well as reviewing the results obtained from recent and ongoing animal experimental studies, and identified a number of weaknesses that may explain the inconsistent outcome in previous trials. As a result of these discussions, the group has agreed to join forces in a new round of experimental work and cell therapy trials in PD, based on a new jointly developed protocol where all these factors are taken into account. In the first instance fetal VM tissue containing mesencephalic DA neuroblasts will be used, with the expectation that this will pave the way for bigger trials using dopaminergic neurons derived from stem cells.

Call for proposal

FP7-HEALTH-2009-single-stage
See other projects for this call

Coordinator

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Address
Trinity Lane The Old Schools
CB2 1TN Cambridge
United Kingdom
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 3 808 371,15
Administrative Contact
Renata Schaeffer (Mr.)

Participants (14)

MAX IV Laboratory, Lund University
Sweden
EU contribution
€ 982 706,24
Address
Paradisgatan 5C
22100 Lund
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Anders Björklund (Prof.)
CARDIFF UNIVERSITY
United Kingdom
EU contribution
€ 1 114 980
Address
Newport Road 30-36
CF24 ODE Cardiff
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Nick Bodycombe (Mr.)
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
United Kingdom
EU contribution
€ 636 024,40
Address
South Kensington Campus Exhibition Road
SW7 2AZ London
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Mike Robinson (Mr.)
UCL Elizabeth Garrett Anderson Institute for Women’s Health
United Kingdom
EU contribution
€ 369 600
Address
Gower Street
WC1E 6BT London
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Greta Borg-Carbott (Ms.)
UNIVERSITAETSKLINIKUM FREIBURG
Germany
EU contribution
€ 2 005 726
Address
Hugstetter Strasse 49
79106 Freiburg
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Gerhard Henninger (Mr.)
LIFE SCIENCE GOVERNANCE INSTITUTE
Austria
EU contribution
€ 213 664,98
Address
Schottenfeldgasse 29
1070 Vienna
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Herbert Gottweis (Prof.)
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
France
EU contribution
€ 756 201
Address
3 Avenue Victoria
75000 Paris
Activity type
Research Organisations
Administrative Contact
Stephane Palfi (Prof.)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
EU contribution
€ 25 849,30
Address
Rue De Tolbiac 101
75654 Paris
Activity type
Research Organisations
Administrative Contact
Annick Bertault (Ms.)
DANDO WEISS & COLUCCI LIMITED

Participation ended

United Kingdom
EU contribution
€ 310 162,14
Address
Lower Bristol Road Minerva House
BA2 9ER Bath
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Isabelle Weiss (Dr.)
LIFE TECHNOLOGIES LIMITED
United Kingdom
EU contribution
€ 173 600
Address
Fountain Drive 3
PA4 9RF Paisley
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Alan Dion (Mr.)
Inomed Medizintechnik GmbH
Germany
EU contribution
€ 73 800
Address
Tullastrasse 5A
79331 Teningen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Rudi Mattmueller (Mr.)
CAMBRIDGE COGNITION LIMITED
United Kingdom
EU contribution
€ 61 650
Address
Tunbridge Court Tunbridge Lane, Bottisham Cambs
CB25 9TU Cambridge
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Andrew Blackwell (Dr.)
SKANE LANS LANDSTING
Sweden
EU contribution
€ 671 759,99
Address
.
291 89 Kristianstad
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Håkan Fornander (Mr.)
IMANOVA LIMITED
United Kingdom
EU contribution
€ 789 999,80
Address
Burlington Danes Building, Imperial College London Hammersmith Hospital, Du Cane Road
W12 0NN London
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Michael Cousins (Mr.)